Table 4

Risk of PPI use among hormone replacement users: multiple regression
Oestrogen-only users No. of GORD cases OR (95% CI) P Tibolone users No. of GORD cases OR (95% CI) P Combined HRT users No. of GORD cases OR (95% CI) P Progestogen users No. of GORD cases OR (95% CI) P
PPI
Hormone 110 21 116 49
Non-hormone 467 467 467 467
OR (95% CI) p 1.34 (1.03–1.74) 0.027 0.76 (0.43–1.37) 0.367 1.15 (0.90–1.47) 0.250 1.50 (1.01–2.22) 0.044
NSAIDs <30d
Hormone 22 2 18 10
Non-hormone 81 81 81 81
OR (95% CI) p 1.57 (1.09–2.26) 0.016 0.83 (0.34–2.08) 0.700 1.57 (1.13–2.19) 0.008 1.15 (0.67–1.98) 0.606
NSAIDs ≥30d
Hormone 56 16 58 24
Non-hormone 200 200 200 200
OR (95% CI) p 2.02 (1.52–2.69) < 0.001 2.55 (1.41–4.63) 0.002 2.37 (1.82–3.07) < 0.001 1.61 (1.05–2.46) 0.029
Calcium <30d
Hormone 1 1 1 0
Non-hormone 11 11 11 11
OR (95% CI) p 0.97 (0.28–3.35) 0.959 2.78 (0.64–12.05) 0.172 1.21 (0.41–3.55) 0.732 3.60 (1.12–11.56) 0.031
Calcium ≥30d
Hormone 12 2 10 0
Non-hormone 29 29 29 29
OR (95% CI) p 1.98 (1.12–3.50) 0.019 2.9 (0.90–9.43) 0.075 1.21 (0.65–2.26) 0.555 1.85 (0.59–5.82) 0.293
Bisphosphonate <30d
Hormone 1 0 0 0
Non-hormone 3 3 3 3
OR (95% CI) p 3.05 (0.70–13.42) 0.139 - (−) 0.999 - (−) 0.999 1.50 (0.14–15.69) 0.737
Bisphosphonate ≥30d
Hormone 6 2 7 0
Non-hormone 18 18 18 18
OR (95% CI) p 1.96 (0.94–4.12) 0.074 1.70 (0.40–7.19) 0.474 2.01 (0.93–4.73) 0.075 1.38 (0.29–6.60) 0.685

This table shows the number of prospective PPI users for hormone replacement use and non-use.

Close et al.

Close et al. BMC Gastroenterology 2012 12:56   doi:10.1186/1471-230X-12-56

Open Data